Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease

European Journal of Medical Research

Volumn 13, Issue 2, 2008, Pages 47-51

  He, W J ^a,b   Hu, Yu ^a,b   Zhang, X P ^a,b   Hong, M ^a,b   Guo, T ^a,b   Wei, W N ^a,b   Song, S J ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Key Laboratory of Biological Targeted Therapy of Hubei Province   (China)

Author keywords

Coagulation; Coronary heart disease; Factor VII; Fibrinolysis; Thrombosis; Tissue factor

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD GROUP ANTIGEN; CHROMOGENIC SUBSTRATE; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTHROMBIN TIME; RISK FACTOR; THROMBIN TIME;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 40749150693     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Amiral J, Fareed J. Thromboembolic disease: biochemical mechanisms and new possibilities of biological diagnosis. Semin Thromb Hemost 1996; 22:41-48.
2. Aurousseau MH, Amiral J, Boffa MC. Level of plasma thrombomodulin in neonates and children. Thromb, Hemost 1991; 65:1232.
3. Avellone G, Di Garbo V, Di Raimondo D, Bono M, Abruzzese G, De Simone R, Raneli G. Evaluation of resistance to activated protein C in myocardial infarction patients. Minerva Cardioangiol. 2001; 49: 363-368.
4. Bauer KA, Rosenberg RD. The pathophysiology of the prothrombotic state in humans: insight gained from studies using analytes of hemostatic system activation. Blood 1987; 70: 343-350.
5. B. L. De Stavola and T. W. Meade. Long-term effects of hemostatic variables on fatal coronary heart disease: 30-year results from the first prospective Northwick Park Heart Study (NPHS-I). J Thromb Haemost. 2007;5:461-471
6. Broze G, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69:150-155.
7. Broze G, Warren J, Novotny LA, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factors Xa: insight into its possible mechanism of action. Blood 1988; 71:335-343.
8. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-2822.
9. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocycteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metab Clin Exp 1998; 47: 273-279.
10. Folsom AR, Wu KK, Rosamond WD, Sharret RA, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997; 96: 1102-1108.
11. Hayashi K, Sone T, Kondoh J, Tsuboi H, Sassa H, Numaguchi Y et al. Prevalence of activated protein C resistance in acute myocardial infarction in Japan. Jpn Heart J. 1997; 38: 769-778.
12. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler Thromb 1994; 14:54-59.
13. Jawed Fareed, Debra A. Hoppensteadt, Fred Leya, Omer Iqbal, Helmut Wolf, and Roger Bick. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44: 1845-1853.
14. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-1544.
15. Kohler HP, Carter AM, Stickland MH, Grant PJ. Level of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Hemost 1998; 79: 14-18.
16. Laffan MA. Activated protein C resistance and myocardial infarction. Heart. 1998; 80: 319-321.
17. Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis FK et al. Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens. 2000; 13: 61-65.
18. Messmore HL, Walenga JM, Fareed J. Molecular analytes of platelet activation. Semin Thromb Hemost 1984; 10: 264-269.
19. Olivot JM, Labreuche J, Aiach M, Amarenco P; GENIC Investigators. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke. 2004; 35: 1946-1951.
20. Porreca E, Di Febbo C, di Castelnuovo A, Baccante G, Amore C, Angelini A et al. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis. 2002; 165: 159-166.
21. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med. 1995; 73: 521-524.
22. Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and haemostasis. Thromb Haemost 1997; 78: 53-59.
23. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res. 1996; 82: 235-244.
24. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999; 353: 1729-1734.
25. Stephens CJM. The antiphospholipid syndrome. Clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolinpin antibodies. Br J Dermatol 1991; 125: 199-210.
26. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost. 2006; 32: 5-10.
27. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factor VII and VIII to incident cardiovascular disease and death in the elderly. Results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-1783.
28. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 1994; 343: 435-439.
29. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol. 2003; 14: 373-375.